NR4A1 and breast cancer: In this prospective translational study, an adjusted breast cancer index (BCI) model with an additional cutpoint identified approximately 20% of patients with invasive, early-stage, hormone receptor–positive N0 breast cancer who had a minimal risk (<5%) of 10-year distant recurrence.